Yousif Capital Management LLC Sells 3,905 Shares of Eli Lilly and Company (NYSE:LLY)

Yousif Capital Management LLC lowered its stake in Eli Lilly and Company (NYSE:LLY) by 3.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 95,665 shares of the company’s stock after selling 3,905 shares during the quarter. Eli Lilly and Company comprises approximately 0.7% of Yousif Capital Management LLC’s investment portfolio, making the stock its 16th biggest holding. Yousif Capital Management LLC’s holdings in Eli Lilly and Company were worth $55,765,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Lipe & Dalton bought a new position in Eli Lilly and Company in the fourth quarter valued at approximately $26,000. Thompson Investment Management Inc. acquired a new stake in shares of Eli Lilly and Company in the third quarter valued at approximately $27,000. Legacy Financial Group LLC acquired a new stake in shares of Eli Lilly and Company in the third quarter valued at approximately $35,000. Optiver Holding B.V. acquired a new stake in shares of Eli Lilly and Company in the third quarter valued at approximately $36,000. Finally, Family CFO Inc acquired a new stake in shares of Eli Lilly and Company in the third quarter valued at approximately $40,000. Institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on LLY. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Barclays boosted their target price on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a report on Wednesday, February 7th. DZ Bank downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price on the stock. in a report on Wednesday, February 21st. Morgan Stanley boosted their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a report on Friday, February 16th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $815.00 target price on shares of Eli Lilly and Company in a report on Monday, April 15th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $728.05.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock traded up $14.29 during trading on Tuesday, reaching $745.62. The company’s stock had a trading volume of 2,041,595 shares, compared to its average volume of 3,051,032. The business’s 50-day moving average price is $763.89 and its 200-day moving average price is $664.05. The firm has a market cap of $708.46 billion, a PE ratio of 128.56, a P/E/G ratio of 1.58 and a beta of 0.34. Eli Lilly and Company has a 52 week low of $370.68 and a 52 week high of $800.78. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. During the same quarter in the prior year, the business posted $2.09 earnings per share. Eli Lilly and Company’s revenue was up 28.1% compared to the same quarter last year. Equities analysts forecast that Eli Lilly and Company will post 12.52 earnings per share for the current year.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the company’s stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the sale, the insider now owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.